Search Results
Jun 15, 2026, 02:52 ET Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
regimens.The AK138D1-202 study focuses on the two major breast cancer subtypes with the greatest unmet need: hormone receptor-positive, HER2-negative (HR+/HER2-) disease, which accounts for approximately 65% of all breast cancers, and triple-negative breast cancer (TNBC), which represents 10-20% of cases.
More news about: Akeso, Inc.
Jun 15, 2026, 02:15 ET SPJIMR's TPO Summit 2026 (Bengaluru edition) fosters dialogue on the future of campus recruitment
Talent Acquisition, APAC & India, Amadeus Software; Neha Srivastava, Senior VP – HR, MetricStream; Sipra Majumdar, Director – People & Culture, SiMa.ai; Sridevi NV, CPO, VTU; and Satender Sighadia, Head – HR, GPS Renewables.For more such news and updates from SPJIMR, visit our
More news about: S.P. Jain Institute of Management & Research (SPJIMR)
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
ruxolitinib solo. El estudio mostró una reducción superior al 50 % en el riesgo de muerte para los pacientes que recibieron la combinación de selinexor (HR 0,43).Reducción del volumen del bazo: se observó un beneficio consistente de SVR35 en todos los subgrupos preespecificados. En particular,
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
comparação com ruxolitinibe sozinho. O estudo mostrou uma redução superior a 50% no risco de morte para os pacientes que receberam a combinação de selinexor (HR 0,43).Redução do volume do baço: O benefício consistente de SVR35 foi observado em subgrupos pré-especificados. Notavelmente, na semana
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:06 ET Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
sekundärer Endpunkt, beobachtet. Die Studie zeigte eine Reduktion des Sterberisikos um mehr als 50 % bei Patienten, die die Selinexor-Kombination erhielten (HR 0,43).Verringerung des Milzvolumens: Ein konsistenter SVR35-Nutzen wurde in allen vorab festgelegten Subgruppen beobachtet. Bemerkenswert
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
combination compared to ruxolitinib alone. The study showed a greater than 50% reduction in the risk of death for patients receiving the selinexor combination (HR 0.43).Spleen Volume Reduction: Consistent SVR35 benefit was observed across prespecified subgroups. Notably, at week 24, superior spleen
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
was not yet mature at this analysis (HR=0.89 [95% CI, 0.57-1.40]), and final testing of OS superiority is planned at a future date. An additional secondary endpoint, time to next treatment (TTNT), consistently favored the pirtobrutinib combination regimen (HR=0.50 [95% CI, 0.35-0.70]; nominal p<0.0001).The
More news about: Eli Lilly and Company
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
follow-up of two years (24.6 months), results showed significant improvement in PFS for Tal-DP (hazard ratio [HR], 0.28; 95 percent confidence interval [CI], 0.20-0.40; p<0.0001) and Tal-D (HR, 0.33; 95% CI, 0.24-0.46; p<0.0001). At 24 months, Tal-DP showed a PFS rate of 81.3% and Tal-D showed a PFS
More news about: Johnson & Johnson
Jun 12, 2026, 14:30 ET कार्यबल की जटिलता बढ़ने के साथ-साथ पेरोल रणनीतिक दृष्टि से महत्वपूर्ण हो गया है: ADP
एक रणनीतिक प्रवर्तक बन रहा है। यह परिवर्तन सटीकता और उत्तरदायित्व के साथ उच्च जोखिम वाले वेतन और HR प्रोसेसों की मैनेजमेंट के लिए विश्वसनीय भागीदारों की बढ़ती आवश्यकता को रेखांकित करता है।वरिष्ठ HR, वित्त तथा पेरोल अग्रणीयों से प्राप्त जानकारियों के आधार पर पूरे भारत की यह रिपोर्ट रेखांकित करती
More news about: ADP, Inc.
Jun 12, 2026, 13:06 ET Rutgers Business School ranks among top MBA programs in the U.S. for return on investment
heavily on cultivating AI talent and developing a strategy for adapting the technology in day-to-day work processes.Fils, who was employed in HR before starting her MBA, flirted with the idea of going into marketing, but returned to the human resources space. "The Rutgers MBA program allowed me
More news about: Rutgers Business School
Jun 12, 2026, 09:52 ET Vortex Companies Promotes Brooke Malone to Senior Vice President of Human Resources
was hired to bring stability to a young HR function and build a scalable foundation that could keep pace with our aggressive growth and expansion," said Mike Vellano, CEO of Vortex Companies. "She has not only excelled at that—she's created a first-class, global HR organization by bringing in the right
More news about: Vortex Companies
Jun 12, 2026, 09:05 ET Jurupa Community Services District Earns National Recognition as a 2026 USA TODAY Top Workplace
people-first cultures. Recipients are determined solely through direct employee feedback collected through a confidential survey conducted by Energage, an HR Research and technology company that has evaluated Top Workplaces since 2006. The survey evaluates key drivers of organizational success, including employee
More news about: Jurupa Community Services District
Jun 12, 2026, 09:00 ET PosterElite Partners with isolved to Simplify Labor Law Poster Compliance for Employers
isolved's software and services to streamline human resource (HR) operations and deliver employee experiences that matter. isolved People Cloud™ is a unified yet modular HCM platform with built-in artificial intelligence (AI) and analytics that connects HR, payroll, benefits, and workforce and talent management
More news about: PosterElite
Jun 12, 2026, 08:01 ET Payroll Moves into Strategic Spotlight as Workforce Complexity Grows: ADP
experience. This shift underscores the growing need for trusted partners to manage high-stakes payroll and HR processes with accuracy and accountability.Drawing on insights from senior HR, finance and payroll leaders across India, the report highlights how rising cost pressures, regulatory changes,
More news about: ADP, Inc.
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
HR (95% CI)Zepzelca vs ControlHR (95% CI)Zepzelca+irinotecan vs Control
More news about: Jazz Pharmaceuticals plc
Jun 12, 2026, 04:49 ET Team Cookie Wins Two Asia-Pacific PR Awards, Marking 3rd Consecutive Year of Success
including SaaS, generative AI, physical AI, robotics, neo-cloud, Web3 gaming, cybersecurity, legaltech, edutech, streaming platforms, K-pop entertech, HR tech, fintech, adtech, healthcare, retail commerce, foodtech, subculture startups, brand builders, martech, and short-form MCNs. Its partner
More news about: Team Cookie
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring Grade 3 (≥2%) adverse events (AEs) in patients receiving the venetoclax-based combination
More news about: AbbVie
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring Grade 3 (≥2%) adverse events (AEs) in patients receiving the venetoclax-based combination
More news about: AbbVie
Jun 11, 2026, 14:32 ET U.S. Office of Personnel Management Selects Oracle to Power Federal Workforce Modernization
accountable HR experience across the federal government."As the foundation for Federal HR 2.0, Oracle Cloud HCM will provide approximately two million U.S. Executive Branch civilian employees with an AI-powered, secure, FedRAMP-authorized HR platform. The solution will centralize HR operations
More news about: Oracle
Jun 11, 2026, 12:37 ET SimpliSafe Strengthens Executive Leadership Team with Three Strategic Appointments
SimpliSafe's foundational commitments to customer trust and privacy. Previously, as Chief Administrative and Legal Officer at Shutterfly, she led legal, HR, compliance, and strategic partnerships and co-chaired the Value Creation Office, helping to drive enterprise-wide initiatives. Additionally, Sharon held
More news about: SimpliSafe
Jun 11, 2026, 12:00 ET PosterElite Honored as PrismHR's 2026 Emerging Partner of the Year for its Positive Impact on PEOs
www.posterelite.com.About PrismHRPrismHR is the leading HR software platform powering PEOs and HR service providers, enabling them to manage payroll, benefits, compliance, and HR for small and medium-sized businesses. PrismHR's Marketplace connects partners and solutions
More news about: PosterElite
Jun 11, 2026, 10:13 ET Seeq Named to Inc.'s 2026 Best Workplaces List
www.inc.com.About Quantum WorkplaceQuantum Workplace, based in Omaha, Nebraska, is an HR technology company that serves organizations through employee-engagement surveys, action-planning tools, exit surveys, peer-to-peer recognition, performance
More news about: Seeq Corporation
Jun 11, 2026, 09:30 ET Healthee Unveils Zoe for HR, an AI Analytics Assistant for Benefits Performance
coverage, Zoe for HR is designed for the people responsible for managing benefits strategy and measuring outcomes."HR teams have access to more benefits data than ever, but turning that data into action remains a challenge," said Ron Zionpour, CTO of Healthee. "Zoe for HR helps HR leaders quickly
More news about: Healthee
Jun 11, 2026, 09:00 ET The Stevie® Awards for Great Employers Final Entry Deadline Extended to July 1
new Solution Provider category.AI Training for HR Professionals is a new Training Program or Media category.20 of the 24 HR Individual categories do not require payment of entry fees, including Human Resources Executive of the Year, HR Rising Star of the Year, Employee Relations Professional
More news about: The Stevie Awards
Jun 11, 2026, 09:00 ET Base10 Partners Hits $2.6B AUM, Closes $850M to Back the Next Wave of Real Economy AI
industry. Base10 has already hosted events this year with CodePath, Anthropic, OpenAI, and other leading tech companies to connect educators, students, and HR leaders navigating the AI transition.The fundraise includes commitments from Base10's limited partner base, including endowments, pensions, sovereign
More news about: Base10 Partners